Please use this identifier to cite or link to this item: https://doi.org/10.1097/JCP.0b013e3181dbfd04
Title: Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: A suicide assessment methodology study report
Authors: Warden, D.
Trivedi, M.H.
Wisniewski, S.R.
Kurian, B.
Zisook, S.
Kornstein, S.G.
Friedman, E.S.
Miyahara, S.
Leuchter, A.F.
Fava, M.
Rush, A.J. 
Keywords: Adherence
Adverse events
Antidepressant
Attrition
Depression
Issue Date: Jun-2010
Source: Warden, D., Trivedi, M.H., Wisniewski, S.R., Kurian, B., Zisook, S., Kornstein, S.G., Friedman, E.S., Miyahara, S., Leuchter, A.F., Fava, M., Rush, A.J. (2010-06). Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: A suicide assessment methodology study report. Journal of Clinical Psychopharmacology 30 (3) : 259-266. ScholarBank@NUS Repository. https://doi.org/10.1097/JCP.0b013e3181dbfd04
Abstract: Adverse events during selective serotonin reuptake inhibitor (SSRI) treatment are frequent and may lead to premature treatment discontinuation. If attrition is associated with early worsening of adverse effects or the frequency, intensity, or burden of adverse effects, interventions to maximize retention could be focused on patients with these events. Outpatient participants (n = 265) with nonpsychotic major depressive disorder entered an 8-week trial with an SSRI. At baseline and week 2, specific adverse effects were evaluated with the Systematic Assessment for Treatment Emergent Events-Systematic Inquiry, and at week 2, the Frequency, Intensity, and Burden of Side Effects Rating globally assessed adverse effects. Attrition was defined by those participants who left treatment after week 2 but before week 8. No specific week 2 adverse effect, either treatment-emergent or with worsening intensity, was independently associated with attrition. Global ratings of adverse effect frequency, intensity, or burden at week 2 were also not associated with subsequent attrition. Neither global ratings nor specific adverse effects at week 2 were related to patient attrition during SSRI treatment. Other factors seem to contribute to patient decisions about continuing with treatment. © 2010 Lippincott Williams & Wilkins.
Source Title: Journal of Clinical Psychopharmacology
URI: http://scholarbank.nus.edu.sg/handle/10635/53419
ISSN: 02710749
DOI: 10.1097/JCP.0b013e3181dbfd04
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

12
checked on Dec 6, 2017

WEB OF SCIENCETM
Citations

11
checked on Nov 22, 2017

Page view(s)

38
checked on Dec 10, 2017

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.